Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 22Leukemia, Myeloid, Acute 21Breast Neoplasms 19Neoplasm Metastasis 16Pancreatic Neoplasms 15Multiple Myeloma 14Prostatic Neoplasms 12Melanoma 12Lymphoma 11Colorectal Neoplasms 11Carcinoma, Renal Cell 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 10Triple Negative Breast Neoplasms 9Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Mouth Neoplasms 8Glioma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Oropharyngeal Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Laryngeal Neoplasms 7Fallopian Tube Neoplasms 7Carcinoma, Hepatocellular 7Carcinoma 7Sarcoma 6Nasopharyngeal Carcinoma 6Endometrial Neoplasms 6

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Penile Neoplasms × Specimen Handling × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡